

Heimildir

- Abu-Naser, D., Gharaibeh, S., Al Meslamani, A. Z., Alefan, Q. og Abunaser, R. (2021). Assessment of extrapyramidal symptoms associated with psychotropics pharmacological treatments, and associated risk factors. *Clinical Practice Epidemiology in Mental Health*, 17, 1-7. 10.2174/1745017902117010001
- Aggarwal, N. K., Rosenheck, R. A., Woods, S. W. og Sernyak, M. J. (2012). Race and long-acting antipsychotic prescription at a community mental health center: A retrospective chart review. *Journal of Clinical Psychiatry*, 73(4), 513-517. 10.4088/JCP.11m07161
- Ali, R. A., Jalal, Z. og Paudyal, V. (2020). Barriers to monitoring and management of cardiovascular and metabolic health of patients prescribed antipsychotic drugs: A systematic review. *BMC Psychiatry*, 20(1), 581. 10.1186/s12888-020-02990-6
- American Psychiatric Association. (2022). *Diagnostic and statistical manual of mental disorders : Dsm-5-tr* (Fifth edition, text revision. útgáfa). American Psychiatric Association Publishing.
- Azfr Ali, R. S., Jalal, Z. og Paudyal, V. (2021). Guidelines versus practice in screening and monitoring of cardiometabolic risks in patients taking antipsychotic medications: Where do we stand? *General Psychiatry*, 34(4), e100561. 10.1136/gpsych-2021-100561
- Barnes, T. R., Bhatti, S. F., Adroer, R. og Paton, C. (2015). Screening for the metabolic side effects of antipsychotic medication: Findings

of a 6-year quality improvement programme in the uk. *BMJ Open*, 5(10), e007633. 10.1136/bmjopen-2015-007633

Bulatova, N., Altaher, N., BaniMustafa, R., Al-Saleh, A., Yasin, H., Zawiah, M., Khalefah, H., Ghilan, M., Al-Lahham, A., Hudaib, M., AlKhawaldeh, B. og Nasr, M. (2022). The effect of antipsychotics and their combinations with other psychotropic drugs on electrocardiogram intervals other than qtc among jordanian adult outpatients. *Biomedicines*, 11(1). 10.3390/biomedicines11010013

Caroff, S. N. og Campbell, E. C. (2016). Drug-induced extrapyramidal syndromes: Implications for contemporary practice. *Psychiatry Clinics of North America*, 39(3), 391-411. 10.1016/j.psc.2016.04.003

Caroff, S. N., Hurford, I., Lybrand, J. og Campbell, E. C. (2011). Movement disorders induced by antipsychotic drugs: Implications of the catie schizophrenia trial. *Neurology Clinics*, 29(1), 127-148, viii. 10.1016/j.ncl.2010.10.002

Cernea, S., Dima, L., Correll, C. U. og Manu, P. (2020). Pharmacological management of glucose dysregulation in patients treated with second-generation antipsychotics. *Drugs*, 80(17), 1763-1781. 10.1007/s40265-020-01393-x

Chakrabarty, A. C., Bennett, J. I., Baloch, T. J., Shah, R. P., Hawk, C. og Natof, T. (2023). Increasing abnormal involuntary movement scale (aims) screening for tardive dyskinesia in an outpatient psychiatry clinic: A resident-led outpatient lean six sigma initiative. *Cureus*, 15(5), e39486. 10.7759/cureus.39486

Collins, E., Tranter, S. og Irvine, F. (2012). The physical health of the seriously mentally ill: An overview of the literature. *Journal of Psychiatric Mental Health Nursing*, 19(7), 638-646. 10.1111/j.1365-2850.2011.01831.x

Cooper, S. J., Reynolds, G. P., With expert, c.-a., Barnes, T., England, E., Haddad, P. M., Heald, A., Holt, R., Lingford-Hughes, A., Osborn, D., McGowan, O., Patel, M. X., Paton, C., Reid, P., Shiers, D. og Smith, J. (2016). Bap guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. *Journal of Psychopharmacology (Oxford, England)*, 30(8), 717-748. 10.1177/026988111664525

Correll, C. U., Solmi, M., Veronese, N., Bortolato, B., Rosson, S., Santonastaso, P., Thapa-Chhetri, N., Fornaro, M., Gallicchio, D., Collantoni, E., Pigato, G., Favaro, A., Monaco, F., Kohler, C., Vancampfort, D., Ward, P. B., Gaughran, F., Carvalho, A. F. og Stubbs, B. (2017). Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: A large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. *World Psychiatry*, 16(2), 163-180. 10.1002/wps.20420

D'Souza, R. S. og Hooten, W. M. (2024). Somatic symptom disorder. *Statpearls*. <https://www.ncbi.nlm.nih.gov/pubmed/30335286>

Darsini, D., Hamidah, H., Notobroto, H. B. og Cahyono, E. A. (2020). Health risks associated with high waist circumference: A systematic review. *Journal of Public Health Research*, 9(2), 1811. 10.4081/jphr.2020.1811

de Toffol, B. (2024). Epilepsy and psychosis. *Revue Neurologique (Paris)*, 180(4), 298-307. 10.1016/j.neurol.2023.12.005

Edinoff, A. N., Ellis, E. D., Nussdorf, L. M., Hill, T. W., Cornett, E. M., Kaye, A. M. og Kaye, A. D. (2022). Antipsychotic polypharmacy-related cardiovascular morbidity and mortality: A comprehensive review. *Neurology International*, 14(1), 294-309. 10.3390/neurolint14010024

- Grover, S., Chakrabarti, S., Kulhara, P. og Avasthi, A. (2017). Clinical practice guidelines for management of schizophrenia. *Indian Journal of Psychiatry*, 59(Suppl 1), S19-S33. 10.4103/0019-5545.196972
- Guerra-Farfan, E., Garcia-Sanchez, Y., Jornet-Gibert, M., Nunez, J. H., Balaguer-Castro, M. og Madden, K. (2023). Clinical practice guidelines: The good, the bad, and the ugly. *Injury*, 54 Suppl 3, S26-S29. 10.1016/j.injury.2022.01.047
- Hirjak, D., Kubera, K. M., Bienentreu, S., Thomann, P. A. og Wolf, R. C. (2019). [antipsychotic-induced motor symptoms in schizophrenic psychoses-part 1 : Dystonia, akathisia und parkinsonism]. *Nervenarzt*, 90(1), 1-11. 10.1007/s00115-018-0582-5
- Huang, P. L. (2009). A comprehensive definition for metabolic syndrome. *Disease Model Mechanism*, 2(5-6), 231-237. 10.1242/dmm.001180
- Kane, J. M., Correll, C. U., Nierenberg, A. A., Caroff, S. N., Sajatovic, M. og Tardive Dyskinesia Assessment Working, G. (2018). Revisiting the abnormal involuntary movement scale: Proceedings from the tardive dyskinesia assessment workshop. *Journal of Clinical Psychiatry*, 79(3). 10.4088/JCP.17cs11959
- Keepers, G. A., Fochtmann, L. J., Anzia, J. M., Benjamin, S., Lyness, J. M., Mojtabai, R., Servis, M., Walaszek, A., Buckley, P., Lenzenweger, M. F., Young, A. S., Degenhardt, A. og Hong, S. H. (2020). The american psychiatric association practice guideline for the treatment of patients with schizophrenia. *American Journal of Psychiatry*, 177(9), 868-872. 10.1176/appi.ajp.2020.177901

- Li, X. Q., Tang, X. R. og Li, L. L. (2021). Antipsychotics cardiotoxicity: What's known and what's next. *World Journal of Psychiatry*, 11(10), 736-753. 10.5498/wjp.v11.i10.736
- Lydon, A., Vallely, J., Tummon, A., Maher, S., Sabri, S., McLoughlin, J., Liew, A., McDonald, C. og Hallahan, B. (2021). Routine screening and rates of metabolic syndrome in patients treated with clozapine and long-acting injectable antipsychotic medications: A cross-sectional study. *Irish Journal of Psychological Medicine*, 38(1), 40-48. 10.1017/ipm.2020.12
- Lög um vísindarannsóknir á heilbrigðissviði nr. 44/2014
- Melamed, O. C., Wong, E. N., LaChance, L. R., Kanji, S. og Taylor, V. H. (2019). Interventions to improve metabolic risk screening among adult patients taking antipsychotic medication: A systematic review. *Psychiatric Services*, 70(12), 1138-1156. 10.1176/appi.ps.201900108
- Mitchell, A. J., Delaffon, V., Vancampfort, D., Correll, C. U. og De Hert, M. (2012). Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: Systematic review and meta-analysis of screening practices. *Psychological Medicine*, 42(1), 125-147. 10.1017/S003329171100105X
- Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W. og Lieberman, J. A. (2012). Pharmacological treatment of schizophrenia: A critical review of the pharmacology and clinical effects of current and future therapeutic agents. *Molecular Psychiatry*, 17(12), 1206-1227. 10.1038/mp.2012.47
- National Institute for Health and Care Excellence. (2014). *Psychosis and schizophrenia in adults: prevention and management Clinical guideline* [CG178] www.nice.org.uk/guidance/cg178

- Nuttall, F. Q. (2015). Body mass index: Obesity, bmi, and health : A critical review. *Nutrition Today*, 50(3), 117-128.
10.1097/NT.0000000000000092
- Patel, J. og Marwaha, R. (2024). Akathisia. Í *Statpearls*.
<https://www.ncbi.nlm.nih.gov/pubmed/30137828>
- Polit, D. F. og Beck, C. T. (2022). *Essentials of nursing research : Appraising evidence for nursing practice* (Tenth edition. útgáfa). Wolters Kluwer.
- Ragnheiður Harpa Arnardóttir. (2021). Aðferðafræði megindlegra rannsókna. Í Sigríður Halldórsdóttir (ritstj.), *Rannsóknir: Handbók í aðferðafræði* (bls. 407-427). Akureyri: Háskólinn á Akureyri.
- Reglugerð um siðanefndir heilbrigðisrannsókna nr 1186/2014
- Reis da Silva, D. A.de Almeida, L. S.Corrêa, L. L.Pimentel, R. F. W.Gomes, A. M. T.Travassos, A. G.Viana, A. M.Cerqueira, M.de Souza, M. C.de Sousa, A. R.Barbosa, P. J. B.Coelho, J. M. F.Magalhaes, L.D'Oliveira Junior, A.Cavalcante Neto, J. L.Santos, C. S.Franca, L. C. M.Brandao, J. L.Dos Santos, L. F. M. (2022). Prevalence and factors associated with metabolic syndrome in patients at a psychosocial care center: A cross-sectional study. *International Journal of Environmental Research and Public Health*, 19(16).
10.3390/ijerph191610203
- Rognoni, C., Bertolani, A. og Jommi, C. (2021). Second-generation antipsychotic drugs for patients with schizophrenia: Systematic literature review and meta-analysis of metabolic and cardiovascular side effects. *Clinical Drug Investigation*, 41(4), 303-319. 10.1007/s40261-021-01000-1
- Romeu-Labayen, M., Tort-Nasarre, G., Rigol Cuadra, M. A., Giralt Palou, R. og Galbany-Estragues, P. (2022). The attitudes of mental

health nurses that support a positive therapeutic relationship: The perspective of people diagnosed with bpd. *Journal of Psychiatric and Mental Health Nursing*, 29(2), 317-326.
10.1111/jpm.12766

Sadock, B. J., Sadock, V. A. og Ruiz, P. (2015). *Kaplan & sadock's synopsis of psychiatry : Behavioral sciences/clinical psychiatry* (Eleventh edition / útgáfa). Wolters Kluwer.

Sarkar, S. og Seshadri, D. (2014). Conducting record review studies in clinical practice. *Journal of Clinical and Diagnostic Research*, 8(9), JG01-04. 10.7860/JCDR/2014/8301.4806

Schneider, R. B., Iourinets, J. og Richard, I. H. (2017). Parkinson's disease psychosis: Presentation, diagnosis and management. *Neurodegenerative Disease Management*, 7(6), 365-376.
10.2217/nmt-2017-0028

Schouby Bock, M., Norgaard Van Achter, O., Dines, D., Simonsen Speed, M., Correll, C. U., Mors, O., Ostergaard, S. D. og Kolbaek, P. (2020). Clinical validation of the self-reported glasgow antipsychotic side-effect scale using the clinician-rated uku side-effect scale as gold standard reference. *Journal of Psychopharmacology*, 34(8), 820-828.
10.1177/0269881120916122

Shah, P., Iwata, Y., Caravaggio, F., Plitman, E., Brown, E. E., Kim, J., Chan, N., Hahn, M., Remington, G., Gerretsen, P. og Graff-Guerrero, A. (2019). Alterations in body mass index and waist-to-hip ratio in never and minimally treated patients with psychosis: A systematic review and meta-analysis. *Schizophrenia Research*, 208, 420-429. 10.1016/j.schres.2019.01.005

Siðanefnd Sjúkrahússins á Akureyri. (e.d.). *Vísindastarf sótt af* :
[Menntun og vísindi | Sjúkrahúsið á Akureyri \(island.is\)](#)

- Simoons, M., Ruhe, H. G., van Roon, E. N., Schoevers, R. A., Bruggeman, R., Cath, D. C., Muis, D., Arends, J., Doornbos, B. og Mulder, H. (2019). Design and methods of the 'monitoring outcomes of psychiatric pharmacotherapy' (mophar) monitoring program- a study protocol. *Bmc Health Services Research*, *19*(1), 125. 10.1186/s12913-019-3951-2
- Siwek, M., Woron, J., Gorostowicz, A. og Wordliczek, J. (2020). Adverse effects of interactions between antipsychotics and medications used in the treatment of cardiovascular disorders. *Pharmacology Reports*, *72*(2), 350-359. 10.1007/s43440-020-00058-6
- Stahl, S. M. og Muntner, N. (2013). *Stahl's essential psychopharmacology : Neuroscientific basis and practical application* (Fourth edition. útgáfa). Cambridge University Press.
- Stogios, N., Smith, E., Bowden, S., Tran, V., Asgariroozbehani, R., McIntyre, W. B., Remington, G., Siskind, D., Agarwal, S. M. og Hahn, M. K. (2022). Metabolic adverse effects of off-label use of second-generation antipsychotics in the adult population: A systematic review and meta-analysis. *Neuropsychopharmacology*, *47*(3), 664-672. 10.1038/s41386-021-01163-7
- Stroup, T. S. og Gray, N. (2018). Management of common adverse effects of antipsychotic medications. *World Psychiatry*, *17*(3), 341-356. 10.1002/wps.20567
- Taylor, D. M., Barnes, T. R. E., & Young, A. H. (2018). *The Maudsley prescribing guidelines in psychiatry* (13th ed.). John Wiley & Sons.
- Waddell, L. og Taylor, M. (2008). A new self-rating scale for detecting atypical or second-generation antipsychotic side effects. *Journal*

of Psychopharmacology, 22(3), 238-243.
10.1177/0269881107087976

Wang, C. H., Lee, T. Y., Hui, K. C. og Chung, M. H. (2019). Mental disorders and medical comorbidities: Association rule mining approach. *Perspectives in Psychiatric Care*, 55(3), 517-526.
10.1111/ppc.12362

Williams, B.Mancia, G.Spiering, W.Agabiti Rosei, E.Azizi, M.Burnier, M.Clement, D. L.Coca, A.de Simone, G.Dominiczak, A.Kahan, T.Mahfoud, F.Redon, J.Ruilope, L.Zanchetti, A.Kerins, M.Kjeldsen, S. E.Kreutz, R.Laurent, S. (2018). 2018 esc/esh guidelines for the management of arterial hypertension. *European Heart Journal*, 39(33), 3021-3104.
10.1093/eurheartj/ehy339

Yaegashi, H., Kirino, S., Remington, G., Misawa, F. og Takeuchi, H. (2020). Adherence to oral antipsychotics measured by electronic adherence monitoring in schizophrenia: A systematic review and meta-analysis. *CNS Drugs*, 34(6), 579-598.
10.1007/s40263-020-00713-9

Zafar, U., Khaliq, S., Ahmad, H. U., Manzoor, S. og Lone, K. P. (2018). Metabolic syndrome: An update on diagnostic criteria, pathogenesis, and genetic links. *Hormones (Athens)*, 17(3), 299-313. 10.1007/s42000-018-0051-3